

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
29 July 2004 (29.07.2004)

PCT

(10) International Publication Number
WO 2004/062568 A2

(51) International Patent Classification⁷:

A61K

(74) Agents: THORESEN, Liv-Heldi et al.; Amersham Health AS, P.O. Box 4220 Nydalen, Nycoveien 1-2, 0401 Oslo (NO).

(21) International Application Number:

PCT/NO2004/000002

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date: 9 January 2004 (09.01.2004)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

20030115 9 January 2003 (09.01.2003) NO

(71) Applicant (for all designated States except US): AMERSHAM HEALTH AS [NO/NO]; Intellectual Property Dept., P.O. Box 4220 Nydalen, Nycoveien 1-2, 0401 Oslo (NO).

(72) Inventors; and

(75) Inventors/Applicants (for US only): SOLBAKKEN, Magne [NO/NO]; Amersham Health AS, P.O. Box 4220 Nydalen, Nycoveien 1-2, 0401 Oslo, NO (NO). ENGELL, Torgrim [NO/NO]; Amersham Health AS, P.O. Box 4220 Nydalen, Nycoveien 1-2, 0401 Oslo (NO). WADSWORTH, Harry, John [GB/GB]; Amersham plc, The Grove Centre, Building 22 AL/18, White Lion Road, HP7 9LL Amersham, Buckinghamshire (GB). ARCHER, Collin, M [US/GB]; The Grove Centre, White Lion Road, HP7 9LL Amersham, Buckinghamshire (GB).

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 2004/062568 A2

(54) Title: CONTRAST AGENT

(57) Abstract: The present invention relates to a contrast agent of Formula I V - L - Z Formula I where V is a non-peptidic vector having affinity for the Angiotensin II receptor, L is a bond, a spacer or a linker moiety and Z represents a moiety detectable in an in vivo imaging procedure of a human or animal body.

CONTRAST AGENT**Field of invention**

The present invention relates to diagnostic contrast agents suitable for use in diagnostic imaging techniques in which a disease state may be imaged using such contrast agents. More particularly the invention relates to contrast agents in which the targeting vector binds to angiotensin II receptors.

Background of invention

Angiotensin II (Ang II) - the octapeptide (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe) - is a pleiotropic vasoactive peptide that binds to two distinct receptors: the Ang II type 1 (AT₁) and type 2 (AT₂) receptors. Activation of the renin-angiotensin-aldosterone system (RAAS) results in vascular hypertrophy, vasoconstriction, salt and water retention, and hypertension. These effects are mediated predominantly by AT₁ receptors. Paradoxically, other Ang II-mediated effects, including cell death, vasodilation, and natriuresis, are mediated by AT₂ receptor activation. The understanding of Ang II signalling mechanisms remains incomplete. AT₁ receptor activation triggers a variety of intracellular systems, including tyrosine kinase-induced protein phosphorylation, production of arachidonic acid metabolites, alteration of reactive oxidant species activities, and fluxes in intracellular Ca²⁺ concentrations. AT₂ receptor activation leads to stimulation of bradykinin, nitric oxide production, and prostaglandin metabolism, which are, in large part, opposite to the effects of the AT₁ receptor. (See: Berry C, Touyz R, Dominiczak AF, Webb RC, Johns DG.: Am J Physiol Heart Circ Physiol. 2001 Dec;281(6):H2337-65. Angiotensin receptors: signalling, vascular pathophysiology, and interactions with ceramide).

Ang II is the active component of the renin-angiotensin-aldosterone system (RAAS). It plays an important physiological role in the regulation of blood pressure, plasma volume, sympathetic nervous activity, and thirst responses. Ang II also has a pathophysiological role in cardiac hypertrophy, myocardial infarction, hypertension, chronic obstructive pulmonary disease, liver fibrosis and atherosclerosis. It is produced systemically via the classical RAAS and locally via tissue RAAS. In the classical RAAS, circulating renal-derived renin cleaves hepatic-derived angiotensinogen to form the decapeptide angiotensin I (Ang I), which is converted by angiotensin-converting enzyme (ACE) in the lungs to the active Ang II. Ang I can also be processed into the heptapeptide Ang-(1-7) by tissue endopeptidases.

The RAAS system is illustrated schematically in Figure 1 hereto which is based on Figure 1 in the article by Foote et al. in Ann. Pharmacother. 27: 1495-1503 (1993).

In addition to the RAAS playing an important role in the normal cardiovascular homeostasis, over activity of the RAAS has been implicated in the development of various cardiovascular diseases, such as hypertension, congestive heart failure, coronary ischemia and renal insufficiency. After myocardial infarction (MI), RAAS becomes activated. Specifically the AT₁ receptor seems to play a prominent role in post-MI remodelling, since AT₁ receptor

expression is increased after MI and in left ventricular dysfunction. Therefore drugs that interfere with RAAS, such as ACE inhibitors and AT₁ receptor antagonists, have been shown to be of great therapeutic benefit in the treatment of such cardiovascular disorders.

For heart, kidneys, lungs and liver alike, fibrosis represents a common pathway to their failure. Understanding pathophysiologic mechanisms involved in organ fibrosis is therefore of considerable interest, particularly given the potential for protective pharmacological strategies. Tissue repair involves inflammatory cells, including members of the monocyte/macrophage lineage, integral to initiating the repair process; and myofibroblasts, phenotypically transformed interstitial fibroblasts, responsible for collagen turnover and fibrous tissue formation. Each of these cellular events in the microenvironment of repair are associated with molecular events that lead to the de novo generation of angiotensin II (Ang II). In an autocrine/paracrine manner, this peptide regulates expression of TGF-beta 1 via angiotensin (AT₁) receptor-ligand binding. It is this cytokine that contributes to phenotypic conversion of fibroblasts to myofibroblasts (myoFb) and regulates myofibroblast turnover of collagen. Angiotensin-converting enzyme (ACE) inhibition or AT₁ receptor antagonism each prevent many of these molecular and cellular responses that eventuate in fibrosis and therefore have been found to be protective interventions.

(See: Weber KT. Fibrosis, a common pathway to organ failure: angiotensin II and tissue repair. *Semin Nephrol.* 1997 Sep;17(5):467-91 and references therein).

Ang II may regulate tissue fibrosis via the activation of mesenchymal cells. For example, Ang II stimulates the proliferation of cardiac fibroblasts *in vitro* via activation of AT₁. The presence of AT₁ receptors has also been demonstrated on cardiac fibroblasts *in vitro*. Most of the profibrotic effects of Ang II appear to be mediated via this receptor; however, increased AT₂ expression on cardiac fibroblasts has been detected in hypertrophied human heart, and the balance between the expressions of these two subtypes may be critical in determining the response to Ang II.

(See: Am. J. Respir. Crit. Care Med., Volume 161, Number 6, June 2000, 1999-2004 Angiotensin II Is Mitogenic for Human Lung Fibroblasts via Activation of the Type 1 Receptor Richard P. Marshall, Robin J. McAnulty, and Geoffrey J. Laurent and references therein).

The Ang II receptors can be distinguished according to inhibition by specific antagonists. AT₁ receptors are selectively antagonized by biphenylimidazoles, such as Losartan, whereas tetrahydroimidazopyridines specifically inhibit AT₂ receptors. The AT₂ receptor may also be selectively activated by CGP-42112A. This is a hexapeptide analog of Ang II, which may also inhibit the AT₂ receptor, depending on concentration). Two other angiotensin receptors have been described: AT₃ and AT₄ subtypes.

In rodents, the AT₁ receptor has two functionally distinct subtypes, AT_{1A} and AT_{1B}, with >95% amino acid sequence homology.

The second major angiotensin receptor isoform is the AT₂ receptor. It has low amino acid sequence homology (~34%) with AT_{1A} or AT_{1B} receptors. Although the exact signalling pathways and the functional roles of AT₂ receptors are unclear, these receptors may antagonize, under physiological conditions, AT₁-mediated actions inhibiting cell growth and by inducing apoptosis and vasodilation. The exact role of AT₂ receptors in cardiovascular disease remains to be defined.

Other receptors for Ang II besides AT₁ and AT₂ are known and are generally referred to as AT_{atypical} (see Kang et al., Am. Heart J. 127: 1388-1401 (1994)).

Description of Related Art

WO 98/18496 (Nycomed Imaging AS) discloses contrast agents comprising Ang II-receptor antagonists labelled for *in vivo* imaging.

US patent no. 5,138,069 discloses substituted imidazoles for use as Ang II receptor blockers. Further, US patent no. 5,264,581 (Cariani) discloses radioiodinated imidazole Ang II antagonists.


The present invention

It has now been found that Ang II-receptor antagonists such as e.g. Losartan, Valsartan, Candesartan and Eprosartan and derivatives thereof labelled with a moiety or moieties detectable *in vivo* are useful diagnostic imaging agents for *in vivo* imaging of a human or animal body.

The contrast agents of the present invention are useful in imaging of Ang II receptor sites *in vivo* i.e. using targeted contrast agents in which the targeting vector has affinity for Ang II-receptor sites. The Ang II receptors are generally located within the cardiovascular system and are accessible to such contrast agents when they are administered into the blood stream. Accordingly, using such targeted contrast agents it is possible to detect diseases and disorders such as heart failure, atherosclerosis and restricted blood flow, as well as other vascular diseases and disorders, and diseases where fibrosis is prominent, and also to monitor the progression of treatment for such diseases and disorders.

Detailed Description of the Invention

In a first aspect, the present invention provides a contrast agent as defined by formula I,



wherein V is a non-peptidic vector having affinity for the Angiotensin II-receptor, L represents a bond, a spacer or linker and Z represents a moiety detectable in an *in vivo* imaging procedure of a human or animal body.

The vector V is a non-peptidic targeting moiety having affinity for the Ang II receptor. V further represents an imidazole Ang II antagonist such as e.g. Losartan, Valsartan, Caldesartan and Eprosartan and derivatives thereof.

The role of the linker L is to couple vector to the imaging moiety, and where L is a spacer moiety the role of L is to distance a relatively bulky imaging moiety, Z, from the active site of the vector, V.

A linker moiety may serve to link one vector to one imaging moiety; alternatively it may link together more than one vector and/or more than one imaging moiety. Likewise an imaging moiety or a vector may be linked to more than one linker. Use in this way of a plurality of imaging moieties (e.g. several linker-imaging moieties attached to one vector or several imaging moieties attached to one linker itself attached to one vector) may enable the detectability of the contrast agent to be increased (e.g. by increasing its radioopacity, echogenicity or relaxivity) or may enable it to be detected in more than one imaging modality. Use in this way of a plurality of vectors may e.g. increase the targeting efficiency of a contrast agent or may make the contrast agent/therapeutic agent able to target more than one site, e.g. different receptors for an agent which has receptor heterogeneity.

The linker moiety L may be a simple bond, glutaric acid, diglycolic acid, PEG units, PEG-like linkers or may be represented by other linkers well known in the art, e.g. as described in WO 01/77145 pages 23-27, the content of which are incorporated herein by reference. L may also be represented by a combination of the linker units.

The imaging moieties (Z) in the compounds of the invention may be any moiety capable of detection either directly or indirectly in an in vivo diagnostic imaging procedure.

For pharmaceuticals useful in diagnosis and particularly in *in vivo* diagnosis the moiety Z must be able to carry the imageable moiety or moieties denoted M. By carrying is meant any form of association between the moiety Z and M such as a chemical bond, e.g. covalent bond or electrovalent or ionic bonds or by absorption or any other kind of association.

Chelating agent of formula (II) and (e) hereafter are particularly preferred.

M can be any imageable moiety. The nature of M will depend of the imaging modality utilised in the diagnosis. M must be capable of detection either directly or indirectly in an in vivo diagnostic imaging procedure. e.g. moieties which emit or may be caused to emit detectable radiation (e.g. by radioactive decay, fluorescence excitation, spin resonance excitation, etc.), moieties which affect local electromagnetic fields (e.g. paramagnetic, superparamagnetic, ferrimagnetic or ferromagnetic species), moieties which absorb or scatter radiation energy

(eg. chromophores, particles (including gas or liquid containing vesicles), heavy elements and compounds thereof, etc.), and moieties which generate a detectable substance (eg. gas microbubble generators).


A wide range of suitable imageable moieties are known from e.g. WO 98/18496, the content of which is incorporated by reference.

Imaging modalities and imageable moieties M are described in more detail hereinafter:

In a first embodiment, the compound of formula (I) comprises a moiety Z carrying one or more imageable moieties M useful in the Radio and SPECT imaging modality. Preferably M is a gamma emitter with low or no alpha- and beta-emission and with a half-life of more than one hour. Preferred groups M are the radionuclides ^{67}Ga , ^{111}In , ^{123}I , ^{125}I , ^{131}I , $^{81\text{m}}\text{Kr}$, ^{99}Mo , $^{99\text{m}}\text{Tc}$, ^{201}Tl and ^{133}Xe . Most preferred is $^{99\text{m}}\text{Tc}$.

When M denotes a metallic radionuclide then Z comprises a chelating agent suitable for forming a stable chelate with M. Such chelating agents are well known from the state of art and typical examples of such chelating agents are described in Table I of WO 01/77145.

Particularly preferred are chelating agents of Formula II



(11)


where:

each R^1 , R^2 , R^3 and R^4 is independently an R group;


each R group is independently H or C₁₋₁₀ alkyl, C₃₋₁₀ alkylaryl, C₂₋₁₀ alkoxyalkyl, C₁₋₁₀

hydroxyalkyl, C₁₋₁₀ alkylamine, C₁₋₁₀ fluoroalkyl, or 2 or more R groups, together with the atoms to which they are attached form a carbocyclic, heterocyclic, saturated or unsaturated ring.

More preferred are chelating agent represented by formulas a, b, c and d.



An even more preferred example a chelating agent is represented by formula e, herein denoted cPn216. Most preferred for Z is when the chelating agent is cPn216 and imaging moiety M is ^{99m}Tc



Conjugates comprising chelating agents of Formula II can be radiolabelled to give good radiochemical purity, RCP, at room temperature, under aqueous conditions at near neutral pH. An advantage of radiolabelling the conjugates at room temperature is a simplified procedure in a hospital pharmacy. For the synthesis of chelating agent of formula II it is referred to WO 03/006070, the content of which are incorporated herein by reference.

Non-metal radionuclides such as ^{123}I , ^{125}I and ^{131}I may be covalently linked to the moiety Z a substitution or addition reaction well known from the state of art.

In a second embodiment, the compound of formula (I) comprises a moiety Z carrying one or more imageable moieties M useful in the PET imaging modality. M then denotes a radioemitter with positron-emitting properties. Preferred groups M are the radionuclides ^{11}C , ^{18}F , ^{68}Ga , ^{13}N , ^{15}O and ^{82}Rb . ^{18}F is specifically preferred.

When M denotes a metallic radionuclide then Z comprises a chelating agent suitable for forming a stable chelate with M. Such chelating agents are well known from the state of art and typical examples of such chelating agents are described in Table I of WO 01/77145 and to the previous part on Radio and SPECT imaging.

In another preferred embodiment Z is the DOTA chelating agent and M is ^{68}Ga which can readily introduced in to the chelate using microwave chemistry.

Non-metal radionuclides such as ^{18}F may be covalently linked to the moiety Z by a substitution or addition reaction well known from the state of art and also described e.g. in WO03/080544 which is hereby incorporated by reference.

In a third embodiment, the compound of formula (I) comprises a moiety Z carrying one or more imageable moieties M useful in the MR imaging modality. M here denotes a paramagnetic metal such those mentioned in US patent 4,647,447, Gd^{3+} , Dy^{3+} , Fe^{3+} and M are particularly preferred and Z comprises a chelating agent, in particular a chelating agent such as acyclic or cyclic polyaminocarboxylates (e.g. DTPA, DTPA-BMA, DOTA and DO3, as described e.g. in US patent 4,647,447 and WO 86/02841. M may also denote metal oxides such as superparamagnetic, ferrimagnetic or ferromagnetic species which are absorbed by e.g. such that Z function as a coating to the metal oxide. Metal oxides for use as MR contrast agents are described e.g. in US patent 6,230,777 which is hereby incorporated by reference.

In a fourth embodiment the compound of formula (I) comprises a moiety Z carrying one or more imageable moieties M useful in the X-ray imaging modality. M here denotes a heavy metal such as W, Au and Bi preferably in the form of oxides which may be absorbed to Z. Iodinated aryl derivatives are particularly well known as X-ray contrast agents, e.g. IopamironTM and OmnipaqueTM.

Ultrasound imaging agents in the form of gas filled microvesicles can be utilised in the imaging of receptors e.g. when they are functionalised for binding to the vector V as described in the state of art e.g. in WO98/18500.


The imaging moiety Z may also represent a chromophore to be used in light imaging procedure. By chromophore is meant a group in a composition of matter, e.g. an organic or inorganic group which absorbs and/or emits light.

By light is meant electromagnetic radiation having wavelengths from 300-1300 nm.


Chromophores having absorption and/or emission maxima in the visible to far infrared range are particularly relevant.

Use of contrast agents for optical imaging with affinity for biological targets can further be provided following the procedures in the state of art e.g. as described in WO 96/17628 which is herewith incorporated by reference.


The invention may be exemplified by Losartan derivatives and is based on attachment of linker (L) and imaging moieties (Z) to the imidazol 5-position. The principle also applies to other compounds having structural similarities, e.g. Valsartan, Candesartan and Eprosartan, possessing suitable anchoring sites in the part of the molecule corresponding to the Losartan imidazole ring.




Losartan



Valsartan




Candesartan




Eprosartan

Scheme 1 shows an example of how the imidazole 5-position can be used to anchor a chelating agent of formula e to give a derivatised Losartan molecule for Tc-chelation. Parent Losartan molecule is transformed to the azide-derivative followed by reduction to the corresponding amine. The amine is reacted with diglycolic anhydride, followed by activation and reaction with a suitable derivative of the chelating agent of formula e.




Scheme 1

Scheme 2 shows an example of the solid phase synthesis of Losartan linker chelating agent conjugate.



Scheme 2

Other examples of related structures are shown below:



The contrast agent of formula (I) are preferably administered as a pharmaceutical formulation comprising the compound of formula (I) in a form suitable for administration to a mammal, such as a human. The administration is suitable carried out by injection or infusion of the formulation such as an aqueous solution. The formulation may contain one or more pharmaceutical acceptable additives and/or excipients e.g. buffers; solubilisers such as cyclodextrins; or surfactants such as Pluronic, Tween or phospholipids. Further, stabilisers or antioxidants such as ascorbic acid, gentisic acid or para-aminobenzoic acid and also bulking agents for lyophilisation such as sodium chloride or mannitol may be added.

The present invention also provides a pharmaceutical composition comprising an effective amount (e.g. an amount effective for enhancing image contrast in an *in vivo* imaging procedure) of a composition of general formula I or a salt thereof, together with one or more pharmaceutically acceptable adjuvants, excipients or diluents.

Viewed from a further aspect the invention provides the use of a composition of formula I for the manufacture of a contrast medium for use in a method of diagnosis involving administration of said contrast medium to a human or animal body and generation of an image of at least part of said body.

Viewed from a still further aspect the invention provides a method of generating enhanced images of a human or animal body previously administered with a contrast agent composition comprising a composition of matter as defined by formula I, which method comprises generating an image of at least part of said body.

The invention further provides a method for the monitoring of the effect of treatment of heart failure and other diseases associated with up-regulation of the AT₁ receptor.

In still another aspect the invention provides a kit for the preparation of a radiopharmaceutical composition of formula (I) comprising a ligand-chelate conjugate and a reducing agent. Preferably the reducing agent is a stannous salt. The kit may further comprise one or more stabilisers, antioxidants, bulking agents for lyophilisation and solubilisers.


The meaning of abbreviations used herein is as follow:


DOTA	- 1,4,7,10-tetraazacyclododecan-1,4,7,10-tetraacetic acid
PEG	- polyethyleneglycol
DIEA	- N,N-diisopropylethylamine
DPPA	- diphenylphosphoryl azide
DBU	- 1,8-diaza-bicyclo (5.4.0) undec-7-ene
DMF	- dimethyl formamide
MDP	- methylene diphosphonate
TFA	- trifluoroacetic acid
THF	- tetrahydro furan
HATU	-N-((dimethylamino)- 1H- 1,2,3 – triazolo [4,5-b]pyridino-1-ylmethylene]-N-methylmethanaminium hexafluorophosphonate N-oxide
Fmoc	- 9-fluorenylmethoxycarbonyl
Boc	- t-butoxycarbonyl
TBTU	- 2-(1H-Benzotriazole-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate
HOBt	- N-hydroxybenzotriazole
TIS	- Triisopropylsilan
NMP	- N-Methylpyrrolidone
MDP	- methylene diphosphonate

The invention is further illustrated by the following non-limiting examples:


Examples

Example 1 Losartan derivatised with biotin



a) Replacement of Losartan hydroxyl group by azide

To a stirred suspension of Losartan (MSD, 0.423 g, 1.00 mmol) and diphenylphosphoryl azide (Aldrich, 0.259 ml, 1.20 mmol) in tetrahydrofuran (8 ml) was added DBU (0.329 ml, 2.20 mmol). After stirring overnight water/acetonitrile (1:1, 4.8 ml) was added and the mixture was filtered. After addition of neat TFA (to pH 2) the mixture was purified by preparative HPLC (column Phenomenex Luna C18(2) 5 μ m 21.2 x 250 mm, solvents: A = water/0.1% TFA and B = acetonitrile/0.1% TFA; gradient 35-45% B over 60 min; flow 10.0 ml/min, UV detection at 214 nm) in several runs to give 99 mg (22%) of the product as white crystals after lyophilisation. Analysis by LC-MS (column Phenomenex Luna C18(2) 3 μ m 50 x 4.60 mm, solvents: A = water/0.1% TFA and B = acetonitrile/0.1% TFA; gradient 20-80% B over 10 min; flow 1 ml/min, UV detection at 214 nm, ESI-MS) gave a peak at 7.3 minutes with m/z 448.1 (MH⁺) corresponding to the structure.

b) Reduction of the azide group to amino function


To a solution of compound from a) (5.0 mg, 0.011 mmol) in methanol (3 ml) was added Pd/C (Koch-Light, ca 10 mg). The mixture was stirred under hydrogen (1 atm) for 10 min, filtered and concentrated. The residue was used in the next step without further work up. LC-MS analysis (column Phenomenex Luna C18(2) 3 μ m 50 x 4.60 mm, solvents: A = water/0.1% TFA and B = acetonitrile/0.1% TFA; gradient 20-80% B over 10 min; flow 1 ml/min, UV

detection at 214 nm, ESI-MS) gave a peak at 1.9 minutes with m/z 422.2 (MH^+) corresponding to the amine.



c) Conjugation of biotin

Biotin (Fluka, 3.0 mg, 0.011 mmol) was activated with HATU (Applied Biosystems, 4.0 mg, 0.011 mmol) and DIEA (2M in NMP, 11 μ l, 0.022 mmol) in DMF (1 ml) for 10 min. The mixture was added to a solution of compound b) (0.011 mmol) in DMF (0.5 ml). After 45 minutes reaction time the product was purified by preparative HPLC (column Phenomenex Luna C18(2) 5 μ m 21.2 x 250 mm, solvents: A = water/0.1% TFA and B = acetonitrile/0.1% TFA; gradient 20-60% B over 60 min; flow 10.0 ml/min, UV detection at 214 nm), giving 2.0 mg (28%) of product after lyophilisation. LC-MS analysis (column Phenomenex Luna C18(2) 3 μ m 50 x 4.60 mm, solvents: A = water/0.1% TFA and B = acetonitrile/0.1% TFA; gradient 10-80% B over 10 min; flow 1 ml/min, UV detection at 214 nm, ESI-MS) gave a peak at 10.6 minutes with m/z 648.6 (MH^+) corresponding to the structure.


Example 2 Losartan derivatised with fluorescein



NHS-Fluorescein (Pierce, 6.0 mg, 0.014 mmol) and DIEA (2M in NMP, 14 μ l, 0.028 mmol) were added to a solution of amino functionalized losartan from Example 1 b) (0.014 mmol) in DMF (1.5 ml). The reaction mixture was left over night. The product was purified by preparative HPLC (column Phenomenex Luna C18(2) 5 μ m 21.2 x 250 mm, solvents: A = water/0.1% TFA and B = acetonitrile/0.1% TFA; gradient 20-80% B over 60 min; flow 10.0 ml/min, UV detection at 214 nm) giving 4.0 mg (37%) after lyophilisation. LC-MS analysis (column Phenomenex Luna C18(2) 3 μ m 50 x 4.60 mm, solvents: A = water/0.1% TFA and B = acetonitrile/0.1% TFA; gradient 20-80% B over 10 min; flow 1 ml/min, UV detection at 214 nm, ESI-MS) gave a peak at 10.4 minutes with m/z 780.8 (MH^+) corresponding to the structure.

Example 3 Losartan derivatised with glutaric acid modified cPn216 for Tc-labellinga) Synthesis of cPn216-glutaric acid intermediate



cPn216 (100 mg, 0.29 mmol) was dissolved in DMF (10 mL) and glutaric anhydride (33 mg, 0.29 mmol) added by portions with stirring. The reaction was stirred for 23 hours to afford complete conversion to the desired product. The pure acid was obtained following RP-HPLC in good yield.

b) Synthesis of tetrafluorothiophenyl ester of cPn216-glutaric acid

To cPn216-glutaric acid (300 mg, 0.66 mmol) in DMF (2 mL) was added HATU (249 mg, 0.66 mmol) and NMM (132 μ L, 1.32 mmol). The mixture was stirred for 5 minutes then tetrafluorothiophenol (0.66 mmol, 119 mg) was added. The solution was stirred for 10 minutes then the reaction mixture was diluted with 20 % acetonitrile/water (8 mL) and the product purified by RP-HPLC yielding 110 mg of the desired product following freeze-drying.

c) Coupling of cPn216-glutaric acid active ester to amino derivatised losartan

To a solution of amino derivatised Losartan from Example 1b) (10 μ mol) in DMF (1 ml) was added N-methylmorpholine (3.3 μ l, 30 μ mol), cPn216-glutaric acid tetrafluorothiophenyl ester from b) (6.8 mg, 11 μ mol, prepared from cPn216 and glutaric acid anhydride by standard methods. After 45 min the reaction mixture was concentrated. The residue was taken up in acetonitrile/water and purified by preparative HPLC (column Vydac 218TP1022 C18 10 μ m, 22 x 250 mm, solvents: A = water/0.1% TFA and B = acetonitrile/0.1% TFA; gradient 10-40% B over 60 min; flow 10.0 ml/min, UV detection at 214 nm) giving 4.2 mg (49%) of product after lyophilisation. LC-MS analysis (column Phenomenex Luna C18(2) 3 μ m 2.0 x 50 mm, solvents: A = water/0.1% HCOOH and B = acetonitrile/0.1% HCOOH; gradient 10-40% B over 10 min; flow 0.3 ml/min, UV detection at 214 and 254 nm, ESI-MS) gave a peak at 6.2 min with m/z at 861.6 (MH^+) as expected. Further characterisation was carried out by NMR spectroscopy confirming the structure.

Example 4 Losartan derivatised with diglycolic acid modified Pn216 for Tc-labellinga) Acylation with diglycolic anhydride


Azide derivatised Losartan from Example 1a) (0.12 mmol) was reduced to the corresponding amine as described under Example 1b). The catalyst was filtered off and diglycolic anhydride (Acros, 70 mg, 0.60 mmol) was added directly to the methanolic solution. After stirring overnight the mixture was concentrated and the residue was purified by preparative HPLC (column Vydac 218TP1022 C18 10 μ m 22 x 250 mm, solvents: A = water/0.1% TFA and B =

acetonitrile/0.1% TFA; gradient 10-40% B over 60 min; flow 10.0 ml/min, UV detection at 254 nm) giving 30 mg (46% over two steps) of white, fluffy material after lyophilisation. Analysis by LC-MS (column Phenomenex Luna C18(2) 3 μ m 2.0 x 50 mm, solvents: A = water/0.1% HCOOH and B = acetonitrile/0.1% HCOOH; gradient 10-80% B over 10 min; flow 0.3 ml/min, UV detection at 214 and 254 nm, ESI-MS) gave a peak at 6.7 min with m/z at 538.0 (MH^+) in accordance with the structure. Further characterisation was carried out by NMR spectroscopy.

b) Conjugation with Pn216

To a solution of Losartan derivative a) (5.4 mg, 0.010 mmol) and HATU (3.8 mg, 0.010 mmol) in DMF (1 ml) was added 2 M DIEA in NMP (15 μ l, 0.030 mmol). The reaction mixture turned yellow and was stirred for 15 min. To the activated carboxylic acid was added a solution of Pn216 (3.4 mg, 0.010 mmol) in DMF (0.25 ml). Progress of the reaction was monitored by analytical HPLC (column Phenomenex Luna C18(2) 3 μ m 4.6 x 50 mm, solvents: A = water/0.1% TFA and B = acetonitrile/0.1% TFA; gradient 10-40% B over 10 min; flow 2.0 ml/min, UV detection at 214 and 254 nm). After 1 hr reaction time a fresh aliquot of HATU (3 mg) was added. After 20 min the reaction had run to completion. The mixture was purified by preparative HPLC (column Vydac 218TP1022 C18 10 μ m 22 x 250 mm, solvents: A = water/0.1% TFA and B = acetonitrile/0.1% TFA; gradient 10-40% B over 60 min; flow 10.0 ml/min, UV detection at 254 nm) giving 4.3 mg (50%) of product after lyophilisation. LC-MS analysis (column Phenomenex Luna C18(2) 3 μ m 2.0 x 50 mm, solvents: A = water/0.1% HCOOH and B = acetonitrile/0.1% HCOOH; gradient 10-40% B over 10 min; flow 0.3 ml/min, UV detection at 214 and 254 nm, ESI-MS) gave a peak at 6.0 min with m/z at 864.3 (MH^+) corresponding to the structure.


Example 5 Losartan derivatised with diglycolic acid modified cPn216 for Tc-labelling




To a solution of Losartan derivative from Example 4a) (5.4 mg, 0.010 mmol) and HATU (3.8 mg, 0.010 mmol) in DMF (1 ml) was added 2 M DIEA in NMP (15 μ l, 0.030 mmol). The reaction mixture turned yellow and was stirred for 15 min. To the activated carboxylic acid was added a solution of cPn216 (3.4 mg, 0.010 mmol) in DMF (0.25 ml). Progress of the reaction was monitored by analytical HPLC (column Phenomenex Luna C18(2) 3 μ m 4.6 x 50 mm, solvents: A = water/0.1% TFA and B = acetonitrile/0.1% TFA; gradient 10-40% B over 10 min; flow 2.0 ml/min, UV detection at 214 and 254 nm). After addition of two more aliquots of

HATU complete conversion of starting material was achieved. The mixture was purified by preparative HPLC (column Phenomenex Luna C18(2) 5 μ m 21.2 x 250 mm, solvents: A = water/0.1% TFA and B = acetonitrile/0.1% TFA; gradient 10-40% B over 60 min; flow 10.0 ml/min, UV detection at 214 nm) to give 3.7 mg (43%) of product after lyophilisation. Analysis by LC-MS (column Phenomenex Luna C18(2) 3 μ m 2.0 x 50 mm, solvents: A = water/0.1% HCOOH and B = acetonitrile/0.1% HCOOH; gradient 10-40% B over 10 min; flow 0.3 ml/min, UV detection at 214 and 254 nm, ESI-MS) gave a peak at 6.1 min with m/z at 863.2 (MH^+) in accordance with the structure. Further characterisation was carried out by NMR spectroscopy.

Example 6 Losartan derivatised with biotin via a PEG linker




a) Conjugation of PEG



Boc-amino PEG acid (Polypure, 6.0 mg, 0.013 mmol) was activated with HATU (5.0 mg, 0.013 mmol) and DIEA (2M in NMP, 13 μ l, 0.026 mmol) in DMF (1 ml) for 5 minutes. The mixture was added to a solution of compound from Example 1b) (0.013 mmol) in DMF (0.5 ml). After 1.5 hrs reaction time the solution was diluted with 30% acetonitrile in water (4 ml) and the product was purified by preparative HPLC (column Phenomenex Luna C18(2) 5 μ m 21.2 x 250 mm, solvents: A = water/0.1% TFA and B = acetonitrile/0.1% TFA; gradient 30-60% B over 60 min; flow 10.0 ml/min, UV detection at 214 nm) giving 5.5 mg (47%) of the

product after lyophilisation. LC-MS analysis (column Phenomenex Luna C18(2) 3 μ m 2.0 x 50 mm, solvents: A = water/0.1% TFA and B = acetonitrile/0.1% TFA; gradient 30-100% B over 10 min; flow 1 ml/min, UV detection at 214 nm, ESI-MS) gave a peak at 7.0 minutes with m/z 900.9 (MH^+) corresponding to the structure.


b) Removal of Boc protection group




Compound a) (5.5 mg, 6.1 μ mol) was dissolved in a 50% solution of TFA in dichloromethane (4 ml). Progress of the reaction was monitored by analytical HPLC (column Phenomenex Luna C18(2) 3 μ m 4.6 x 50 mm, solvents: A = water/0.1% TFA and B = acetonitrile/0.1% TFA; gradient 10-40% B over 10 min; flow 2.0 ml/min, UV detection at 214 and 254 nm) which proved that the cleavage was completed after 20 min, t_R = 6.1 min. Analysis by MS (direct injection (solvents: A = water/0.1% TFA and B = acetonitrile/0.1% TFA; 50% B over 2 min; flow 0.3 ml/min, ESI-MS) gave m/z at 800.7 (MH^+) corresponding to the amine. The solution was concentrated and the product was used in the next step without further purification.

c) Conjugation of biotin

Biotin (Fluka, 1.0 mg, 4.0 μ mol) was activated with HATU (1.5 mg, 4.0 μ mol) and DIET (2M in NMP, 4.5 μ l, 9.0 μ mol) in DMF (1 ml) for 10 min and then added to a solution of compound b) (3.0 μ mol) in DMF (1.5 ml). The reaction mixture was stirred for 15 min, diluted with 20% acetonitrile in water and purified by preparative HPLC (column Phenomenex Luna C18(2) 5 μ m 21.2 x 250 mm, solvents: A = water/0.1% TFA and B = acetonitrile/0.1% TFA; gradient 20-60% B over 60 min; flow 10.0 ml/min, UV detection at 214 nm) giving 2.4 mg (81%) of product. Analysis by MS direct injection (solvents: A = water/0.1% TFA and B = acetonitrile/0.1% TFA; 50% B over 2 min; flow 0.3 ml/min, ESI-MS) gave m/z at 1026.8 (MH^+) corresponding to the structure.

Example 7 Losartan derivatised with fluorescein via a PEG linker


NHS-Fluorescein (Pierce, 2 mg, 4 μ mol) and DIET (2M in NMP, 4.5 μ l, 9.0 μ mol) were added to a solution of compound from Example 6 b) (3 μ mol) in DMF (1.5 ml). The reaction was left over night. After dilution with 30% acetonitrile and adjustment of pH to 2 (TFA) the product was purified by preparative HPLC (column Phenomenex Luna C18(2) 5 μ m 21.2 x 250 mm, solvents: A = water/0.1% TFA and B = acetonitrile/0.1% TFA; gradient 30-60% B over 60 min; flow 10.0 ml/min, UV detection at 214 nm) giving 2.5 mg (72%) after lyophilisation. Analysis by MS direct injection (solvents: A = water/0.1% TFA and B = acetonitrile/0.1% TFA; 50% B over 2 min; flow 0.3 ml/min, ESI-MS) gave m/z at 1158.5 (MH^+) in accordance with the structure.

Example 8 Losartan derivatised with PEG-glutaric acid-cPn216 for Tc-labelling


DIET (2M in NMP, 8 μ l, 16 μ mol) and a solution of cPn216-succinic acid tetrafluorothiophenyl ester from Example 3b) (5 mg, 8 μ mol) in DMF (0.5 ml) were added to a solution of compound from Example 6b) (4 μ mol) in DMF (1.5 ml). After stirring overnight the reaction mixture was diluted with water (3 ml) and pH was adjusted to 2 by addition of TFA. The product was purified by preparative HPLC (column Phenomenex Luna C18(2) 5 μ m 21.2 x 250 mm, solvents: A = water/0.1% TFA and B = acetonitrile/0.1% TFA; gradient 20-60% B over 60 min; flow 10.0 ml/min, UV detection at 214 nm) giving 2.0 mg (40%) after lyophilisation. Analysis by MS direct injection (solvents: A = water/0.1% TFA and B =

acetonitrile/0.1% TFA; 50% B over 2 min; flow 0.3 ml/min, ESI-MS) gave m/z at 1239.8 (MH^+) corresponding to the structure.

Example 9 Losartan derivatised with PEG-diglycolic acid-cPn216 for Tc-labelling



a) Acylation with diglycolic anhydride




Compound from Example 6b) (5.0 μmol) was dissolved in methanol (2.5 ml) and pH was adjusted to 9 by addition of DIEA. To the solution was added diglycolic anhydride (Acros, 1.2 mg, 10 μmol). After 50 minutes the reaction mixture was concentrated and the residue was purified by preparative HPLC (column Phenomenex Luna C18(2) 5 μm 21.2 x 250 mm, solvents: A = water/0.1% TFA and B = acetonitrile/0.1% TFA; gradient 20-60% B over 60 min; flow 10.0 ml/min, UV detection at 214 nm) giving 4.5 mg (98%) of the product. Analysis by MS direct injection (solvents: A = water/0.1% TFA and B = acetonitrile/0.1% TFA; 50% B over 2 min; flow 0.3 ml/min, ESI-MS; m/z 916.9 (MH^+)) was in accordance with the structure.

b) Conjugation of cPn216


Compound a) (5 μmol) was dissolved in DMF (2 ml) and activated with HATU (2 mg, 5 μmol) and DIEA (2M in NMP, 5 μl , 10 μmol) for 5 minutes. cPn216 (3.4 mg, 10 μmol) was added

(column Phenomenex Luna C18(2) 5 μ m 21.2 x 250 mm, solvents: A = water/0.1% TFA and B = acetonitrile/0.1% TFA; gradient 20-60% B over 60 min; flow 10.0 ml/min, UV detection at 214 nm) giving 3.7 (57%) mg after lyophilisation. LC-MS analysis (column Phenomenex Luna C18(2) 3 μ m 2.0 x 50 mm, solvents: A = water/0.1% formic acid and B = acetonitrile/0.1% formic acid; gradient 10-40% B over 10 min; flow 1 ml/min, UV detection at 214 nm, ESI-MS) gave a peak at 6.8 minutes with m/z 1241.2 (MH^+) corresponding to the structure.

Example 10 Solid phase synthesis of Losartan modified with cPn216 via a PEG-glutaric acid linker




a) Attachment of Losartan to methoxytrityl resin



To a suspension of 4-methoxytrityl chloride resin from Novabiochem (53 mg, corresponding to 0.050 mmol) in dichloromethane (1 ml) was added a solution of Losartan (MSD, 42 mg, 0.10 mmol) in DMF (0.5 ml) and DIEA (2 M solution in NMP, 0.10 ml, 0.20 mmol). The mixture was kept at a roller table for 4 days. The resin was drained and washed with DMF and dichloromethane several times. An aliquot of the resin was cleaved (5% TFA and 5% TIS in dichloromethane, 15 min) and analysed by HPLC (column Phenomenex Luna C18(2) 3 μ m 4.6 x 50 mm, solvents: A = water/0.1% TFA and B = acetonitrile/0.1% TFA; gradient 10-80%


B over 10 min; flow 2.0 ml/min, UV detection at 214 and 254 nm), giving a peak coeluting with Losartan.

b) Azide formation



The reaction was carried out in a manual nitrogen bubbler apparatus. To a suspension of the resin from a) above in THF (ca 1 ml) was added DBU (16 μ l, 0.11 mmol) and diphenylphosphoryl azide (Aldrich, 13 μ l, 0.060 mmol). After ca 30 min fresh aliquots of diphenylphosphoryl azide (7 μ l) and DBU (8 μ l) were added. After 45 min an aliquot of the resin was cleaved (CH₂Cl₂/TFA/TIS, 97.5:2.5) and analysed by LC-MS (column Phenomenex Luna C18(2) 3 μ m 2.0 x 50 mm, solvents: A = water/0.1% HCOOH and B = acetonitrile/0.1% HCOOH; gradient 10-80% B over 10 min; flow 0.3 ml/min, UV detection at 214 and 254 nm, ESI-MS) giving a peak at 8.8 min with m/z at 447.9 (MH^+) corresponding to the azide. No trace of starting material could be observed.

c) Reduction of the azide to corresponding amine



The reaction was run in a manual nitrogen bubbler apparatus. To a solution of tin(II)chloride dihydrate (23 mg, 0.10 mmol) in THF (0.5 ml) was added thiophenol (41 μ l, 0.40 mmol) and triethylamine (42 μ l, 0.30 mmol). More THF was added until the precipitate was almost dissolved. The mixture was transferred to an aliquot of the resin from b) above (formally corresponding to 0.05 mmol azide) covered with THF (0.5 ml). After 1 hr reaction time the reagent solution was drained off and the resin was washed with THF, DMF and methanol.


An aliquot of the resin was cleaved ($\text{CH}_2\text{Cl}_2/\text{TFA/TIS}$, 97.5:5:2.5) and analysed by LC-MS (column Phenomenex Luna C18(2) 3 mm 2.0 \times 50 mm, solvents: A = water/0.1% HCOOH and B = acetonitrile/0.1% HCOOH; gradient 10-80% B over 10 min; flow 0.3 ml/min, UV detection at 214 and 254 nm, ESI-MS) showing complete conversion of starting material to a more hydrophilic product eluting at 4.6 min with m/z at 421.7 (MH^+) corresponding to the amine.


d) Coupling of the PEG-glutaryl-cPn216 units

The reaction was run in a manual nitrogen bubbler apparatus. A mixture of Fmoc-amino PEG-diglycolic acid (Polypure AS, 40 mg, 0.075 mmol), TBTU (24 mg, 0.075 mmol), HOBt (12 mg, 0.075 mmol) and 2 M DIEA in DMF (75 μl , 0.15 mmol) in DMF (0.5 ml) was added to the resin. After two hours the resin was drained and washed with DMF. Kaiser test was negative. The Fmoc group was cleaved by standard treatment with 20% piperidine in DMF.


To an aliquot of the resin (formally 0.02 mmol) suspended in DMF (2 ml) were added cPn216-glutaric acid tetrafluorothiophenyl ester from Example 3b) (25 mg, 0.040 mmol), HOBt (6 mg, 0.04 mmol) and 2 M DIEA (30 μl , 0.060 mmol). After two hours reaction time the product was cleaved off the resin ($\text{CH}_2\text{Cl}_2/\text{TFA/TIS}$, 97.5:5:2.5). The cleavage solution was concentrated and the residue was purified by preparative HPLC (column Phenomenex Luna C18(2) 5 mm 21.2 \times 250 mm, solvents: A = water/0.1% TFA and B = acetonitrile/0.1% TFA; gradient 20-30% B over 60 min; flow 10.0 ml/min, UV detection at 214 nm) to give 0.1 mg of product after lyophilisation. Analysis by LC-MS (column Phenomenex Luna C18(2) 3 mm 2.0 \times 50 mm, solvents: A = water/0.1% HCOOH and B = acetonitrile/0.1% HCOOH; gradient 10-80% B over 10 min; flow 0.3 ml/min, UV detection at 214 and 254 nm, ESI-MS) gave a peak at 4.3 min with m/z at 1151.4 corresponding to MH^+ of the correct structure.

Example 11 Solid phase synthesis of Losartan modified with cPn216 via a PEG-glutaric acid linker




a) Attachment of Losartan to trityl derivatised solid support

Losartan (MSD, 0.236 g, 0.558 mmol) and triethylamine (Fluka, 0.233 ml, 1.67 mmol) were added to a suspension of trityl chloride resin (Novabiochem, substitution 1.24 mmol/g, 0.300 g) in DMF (5 ml). After 4 days the resin was drained and washed. An aliquot of the resin was cleaved (dichloromethane/ TFA/ triisopropylsilane, 92.5: 5.0: 2.5, 15 min). HPLC analysis (column Phenomenex Luna C18(2) 3 μ m 4.6 x 50 mm, solvents: A = water/0.1% TFA and B = acetonitrile/0.1% TFA; gradient 10-40% B over 10 min; flow 2.0 ml/min, UV detection at 214 and 254 nm) gave a peak with t_R 6.7 minutes corresponding to Losartan. The resin was treated with dichloromethane/methanol/diisopropylethylamine solution (17 : 2 : 1, 20 ml, 1 h), washed with dichloromethane and dried.

b) Replacement of the hydroxyl group by azide

Diphenylphosphoryl azide (Aldrich, 0.481 ml, 2.23 mmol) and DBU (0.611 ml, 4.09 mmol) were added to a suspension of resin bound Losartan from a) (0.372 mmol) in THF (10 ml). The reaction was left over night. An aliquot of the resin was cleaved as described under a). Analysis by LC-MS (column Phenomenex Luna C18(2) 3 μ m 50 x 4.60 mm, solvents: A = water/0.1% TFA and B = acetonitrile/0.1% TFA; gradient 20-80% B over 10 min; flow 1 ml/min, UV detection at 214 nm, ESI-MS) gave a peak, t_R 7.3 minutes, with m/z 448.1 (MH^+) corresponding to the structure.

c) Reduction of the azide group to amine

To a suspension of the resin from b) in THF (4 ml) was added addition of tin(II)chloride (Acros, 0.141 g, 0.744 mmol), thiophenol (Fluka, 0.304 ml, 2.976 mmol) and triethylamine (Fluka, 0.311 ml, 2.23 mmol). After 1.5 hour an aliquot of the resin was cleaved as described under a). LC-MS analysis (column Phenomenex Luna C18(2) 3 μ m 50 x 4.60 mm, solvents: A = water/0.1% TFA and B = acetonitrile/0.1% TFA; gradient 20-80% B over 10 min; flow 1 ml/min, UV detection at 214 nm, ESI-MS) gave a peak at 1.9 minutes with m/z 422.2 (MH^+) as expected for amine.

d) Conjugation of the PEG-glutaryl-cPn216 units

The reaction was run in a manual nitrogen bubbler apparatus. A mixture of Fmoc-PEG propionic acid (Polypure AS, 72 mg, 0.086 mmol), HATU (Applied Biosystems, 33 mg, 0.086 mmol) and DIEA (Fluka, 29 μ l, 0.172 mmol) in DMF (2 ml) was added to the resin from c) (0.043 mmol). After 2.5 hours the resin was drained and washed with DMF. Kaiser test was negative. The Fmoc group was cleaved by standard treatment with 20% piperidine in DMF. To the resin in DMF (1.5 ml) were added cPn216-glutaric acid tetrafluorothiophenyl ester from Example 3b) (53 mg, 0.086 mmol) and DIEA (15 μ l, 0.086 mmol). The reaction was left over night, Kaiser test was negative. The product was cleaved off the resin (CH₂Cl₂/TFA/TIS, 97.5:5:2.5). The cleavage solution was concentrated and the product was purified by preparative HPLC (column Phenomenex Luna C18(2) 5 μ m 21.2 x 250 mm, solvents: A = water/0.1% TFA and B = acetonitrile/0.1% TFA; gradient 10-40% B over 60 min; flow 10.0 ml/min, UV detection at 214 nm) giving 3.8 mg after lyophilisation. Analysis by LC-MS (column Phenomenex Luna C18(2) 3 μ m 2.0 x 50 mm, solvents: A = water/0.1% HCOOH and B = acetonitrile/0.1% HCOOH; gradient 10-40% B over 10 min; flow 0.3 ml/min, UV detection at 214 and 254 nm, ESI-MS) gave a peak at 7.2 min with m/z at 1460.6 corresponding to MH^+ of the correct structure. Further characterisation was carried out by NMR spectroscopy.

General ^{99m}Tc-Labeling protocol

A preparation is made by dissolving 0,1 mg freeze-dried cPn216 derived compound in 0,2 ml (distilled and oxygen-free) water. This solution is transferred into a 10 ml nitrogen filled vial.

0,5 ml carbonate buffer, 0,5 ml $\text{Na}^{99m}\text{TcO}_4$ solution and 0,1 ml Sn-MDP s

The preparation is left at room temperature for 20 minutes.

Carbonate buffer: The carbonate buffer has a pH of 9,2 and contains 8,4 10,6 mg Na_2CO_3 per ml water. It is purged with nitrogen gas for at least 1 use.

$\text{Na}^{99m}\text{TcO}_4$ solution: Technetium generator (e.g. Ifetec generator) eluate, radioactive concentration of 2 GBq/ml, oxygen free.

Sn-MDP solution: This solution contains 0,131 mg $\text{SnCl}_2 \cdot 2\text{H}_2\text{O}$ and 0,92% (methylene diphosphonate) per ml water. The solution is made freshly before continuous nitrogen gas purging.

Claims


1. A compound of the general formula I:



or pharmaceutically acceptable salt thereof, wherein V is a non-peptidic vector having affinity for the Angiotensin II receptor L is a bond, a spacer or a linker moiety and Z represents a moiety detectable in an *in vivo* imaging procedure of a human or animal body.

2. A compound according to claim 1 wherein V is Losartan, Valsartan, Candesartan, Eprosartan or derivatives thereof.

3. A compound as claimed in any of the previous claims where Z is a chelating agent of Formula II carrying an imageable moiety M




(II)

where:

each R^1 , R^2 , R^3 and R^4 is independently an R group;

each R group is independently H or C₁₋₁₀ alkyl, C₃₋₁₀ alkylaryl, C₂₋₁₀ alkoxyalkyl, C₁₋₁₀ hydroxyalkyl, C₁₋₁₀ alkylamine, C₁₋₁₀ fluoroalkyl, or 2 or more R groups, together with the atoms to which they are attached form a carbocyclic, heterocyclic, saturated or unsaturated ring.

4. A compound as claimed in any of the previous claims where Z is a chelating agent of formula e carrying an imageable moiety M



e

5. A compound as claimed in any of the previous claims wherein Z comprises an imaging moiety wherein the imaging moiety comprises metal radionuclides, paramagnetic metal ions, fluorescent metal ions, chromophores, heavy metal ions or cluster ions.

6. A compound as claimed in claims 3-5 wherein the imaging moiety comprises ^{90}Y , $^{99\text{m}}\text{Tc}$, ^{111}In , ^{47}Sc , ^{67}Ga , ^{51}Cr , $^{177\text{m}}\text{Sn}$, ^{67}Cu , ^{167}Tm , ^{97}Ru , ^{188}Re , ^{177}Lu , ^{199}Au , ^{203}Pb , ^{141}Ce or ^{18}F .

7. A pharmaceutical composition comprising an effective amount of a compound of general Formula (I) or a salt thereof, together with one or more pharmaceutically acceptable adjuvants, excipients or diluents for use in enhancing image contrast in *in vivo* imaging or for treatment of a disease.

8. Use of a compound as claimed in any one of claims 1 to 6 in the preparation of a contrast medium for use in a method of diagnosis involving administering said contrast medium to a human or animal body and generating an image of at least part of said body.

9. A method of generating images of a human or animal body involving administering a contrast agent to said body, and generating an image of at least a part of said body to which said contrast agent has distributed, characterised in that said contrast agent comprises a compound as claimed in any one of claims 1 to 6.

10. A method of generating enhanced images of a human or animal body previously administered with a contrast agent composition comprising a compound as claimed in claims 1 to 6, which method comprises generating an image of at least part of said body.

Figure 1 - The RAAS system

1 / 1




FIG. 1

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
29 July 2004 (29.07.2004)

PCT

(10) International Publication Number
WO 2004/062568 A3

(51) International Patent Classification⁷: A61K 51/04, 49/08, 49/00

(21) International Application Number: PCT/NO2004/000002

(22) International Filing Date: 9 January 2004 (09.01.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: 20030115 9 January 2003 (09.01.2003) NO

(71) Applicant (for all designated States except US): AMERSHAM HEALTH AS [NO/NO]; Intellectual Property Dept., P.O. Box 4220 Nydalen, Nycoveien 1-2, 0401 Oslo (NO).

(72) Inventors; and

(75) Inventors/Applicants (for US only): SOLBAKKEN, Magne [NO/NO]; Amersham Health AS, P.O. Box 4220 Nydalen, Nycoveien 1-2, 0401 Oslo, NO (NO). ENGELL, Torgrim [NO/NO]; Amersham Health AS, P.O. Box 4220 Nydalen, Nycoveien 1-2, 0401 Oslo (NO). WADSWORTH, Harry, John [GB/GB]; Amersham plc, The Grove Centre, Building 22 AL/18, White Lion Road, HP7 9LL Amersham, Buckinghamshire (GB). ARCHER, Colin, M [US/GB]; The Grove Centre, White Lion Road, HP7 9LL Amersham, Buckinghamshire (GB).

(74) Agents: THORESEN, Liv-Helga et al.; Amersham Health AS, P.O. Box 4220 Nydalen, Nycoveien 1-2, 0401 Oslo (NO).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: CONJUGATE OF LOSARTAN, VALSARTAN, CANDESARTAN OR EPROSARTAN AND A CHELANT AS CONTRAST AGENT

WO 2004/062568 A3



(57) Abstract: The present invention relates to a contrast agent of Formula (I) V-L-Z; Where V is a non-peptidic vector having affinity for the Angiotensin II receptor, L is a bond, a spacer or a linker moiety and Z represents a moiety detectable in an in vivo imaging procedure of a human or animal body.



Published:

- *with international search report*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(88) Date of publication of the international search report:

30 September 2004

INTERNATIONAL SEARCH REPORT

International Application No

PCT/N02004/000002

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 A61K51/04 A61K49/08 A61K49/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
 IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, CHEM ABS Data, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98/18496 A (COCKBAIN JULIAN ; KLAIVENESS JO (NO); NAEVESTAD ANNE (NO); CUTHBERTSON) 7 May 1998 (1998-05-07) cited in the application page 5 - page 9 page 46 - page 47; claims 6,10-12; examples 2,5	1,2,5-10
X	WO 01/92283 A (COLLINS DOUGLAS A ; MAYO FOUNDATION (US); UNIV MINNESOTA (US); HOGENKA) 6 December 2001 (2001-12-06) page 4, paragraph 6 page 11, paragraph 10 - page 12, paragraph 3 page 76 - page 77 page 109; claims 26,29-32,35,42,54-58	1,2,5-10

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the International filing date
- *L* document which may throw doubts on priority, claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the International search

7 July 2004

Date of mailing of the International search report

19/07/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Gonzalez Ramon, N

INTERNATIONAL SEARCH REPORT

International Application No

PCT/NO2004/000002

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	PATENT ABSTRACTS OF JAPAN vol. 1997, no. 10, 31 October 1997 (1997-10-31) & JP 9 165378 A (SEITAI KINOU KENKYUSHO:KK), 24 June 1997 (1997-06-24) abstract -----	1,5-10
Y	WO 01/77145 A (INDREVOLL BAARD ; CUTHBERTSON ALAN (NO); NYCOMED IMAGING AS (NO)) 18 October 2001 (2001-10-18) cited in the application claims 16,17,24-26; example 6; table 1 -----	1-10
Y	WO 02/070018 A (MENDIZABAL MARIVI ; AMERSHAM PLC (GB); DIXON MARK (GB); STOREY ANTHONY) 12 September 2002 (2002-09-12) claims 3,4,6; table 1 -----	1-10
P,Y	WO 03/006491 A (INDREVOLL BAARD ; SOLBAKKEN MAGNE (NO); AMERSHAM HEALTH AS (NO); CUTHB) 23 January 2003 (2003-01-23) page 10; claims 12-17,23-25; example 1 -----	1-10
P,Y	WO 03/006070 A (ARCHER COLIN MILL ; AMERSHAM PLC (GB); WADSWORTH HARRY JOHN (GB); ENGE) 23 January 2003 (2003-01-23) page 4; claims 13-15; examples 5,6 -----	1-10

INTERNATIONAL SEARCH REPORT

International application No.
PCT/N02004/000002

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 9,10 are directed to a diagnostic method practised on the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/NO2004/000002

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9818496	A 07-05-1998	AT 249247 T		15-09-2003
		AU 733495 B2		17-05-2001
		AU 4786697 A		22-05-1998
		AU 4786897 A		22-05-1998
		AU 4786997 A		22-05-1998
		BG 103438 A		31-01-2000
		BR 9712683 A		19-10-1999
		CA 2270120 A1		07-05-1998
		CN 1440816 A		10-09-2003
		CN 1234742 A		10-11-1999
		CZ 9901494 A3		15-09-1999
		DE 69724817 D1		16-10-2003
		DE 69724817 T2		01-07-2004
		EP 0973552 A2		26-01-2000
		EP 0971747 A2		19-01-2000
		EP 0946202 A2		06-10-1999
		ES 2206689 T3		16-05-2004
		WO 9818501 A2		07-05-1998
		WO 9818496 A2		07-05-1998
		WO 9818497 A2		07-05-1998
		JP 2001503407 T		13-03-2001
		KR 2000052829 A		25-08-2000
		NO 991889 A		28-06-1999
		NZ 335596 A		27-10-2000
		US 6264914 B1		24-07-2001
		US 6051207 A		18-04-2000
		US 2003228254 A1		11-12-2003
		US 2002102215 A1		01-08-2002
		US 2001016587 A1		23-08-2001
		US 6264917 B1		24-07-2001
		US 6261537 B1		17-07-2001
		AU 4786797 A		22-05-1998
		EP 0991427 A2		12-04-2000
		WO 9818495 A2		07-05-1998
		JP 2002515889 T		28-05-2002
		AU 4787097 A		22-05-1998
		EP 0963209 A2		15-12-1999
		WO 9818498 A2		07-05-1998
		JP 2001502719 T		27-02-2001
		AU 733477 B2		17-05-2001
		AU 4718297 A		22-05-1998
		BG 103439 A		31-01-2000
		BR 9713978 A		02-05-2000
		CA 2269985 A1		07-05-1998
		CN 1238700 A		15-12-1999
		EP 1007101 A2		14-06-2000
		WO 9818500 A2		07-05-1998
		HU 0000357 A2		28-06-2000
WO 0192283	A 06-12-2001	AU 6972901 A		11-12-2001
		WO 0192283 A2		06-12-2001
		US 2002049155 A1		25-04-2002
JP 9165378	A 24-06-1997	NONE		
WO 0177145	A 18-10-2001	AU 5068301 A		23-10-2001
		CA 2405469 A1		18-10-2001
		CN 1436195 T		13-08-2003

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/NO2004/000002

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 0177145	A	EP	1272507 A2	08-01-2003
		JP	2003531835 T	28-10-2003
		WO	0177145 A2	18-10-2001
		US	2003204049 A1	30-10-2003
WO 02070018	A 12-09-2002	CA	2439579 A1	12-09-2002
		EP	1368064 A2	10-12-2003
		WO	02070018 A2	12-09-2002
WO 03006491	A 23-01-2003	BR	0210886 A	22-06-2004
		BR	0210965 A	08-06-2004
		CA	2450690 A1	23-01-2003
		CA	2452923 A1	23-01-2003
		EP	1404377 A2	07-04-2004
		EP	1404371 A2	07-04-2004
		WO	03006070 A2	23-01-2003
		WO	03006491 A2	23-01-2003
WO 03006070	A 23-01-2003	BR	0210886 A	22-06-2004
		BR	0210965 A	08-06-2004
		CA	2450690 A1	23-01-2003
		CA	2452923 A1	23-01-2003
		EP	1404377 A2	07-04-2004
		EP	1404371 A2	07-04-2004
		WO	03006070 A2	23-01-2003
		WO	03006491 A2	23-01-2003